Bessemer Group Inc. lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 21,126.8% duri

ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Ou

Wall Street analysts change outlook on top names. See all rating changes, including upgrades and dow

Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises

Allspring Global Investments Holdings LLC lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: A

-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s dise

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will

Principal Accounting Officer James Kihara sold 11,421 shares for a transaction value of approximatel

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperfo

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointme

B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy

Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commis

Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by

Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend i

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a B

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is cele

Acadia shares rise after CHMP recommends DAYBU for Rett syndrome in the European Union, reversing an

Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small

U.S. stocks slightly up, Dow Jones gains 0.1%. Health care shares jump 2.8%, ON Semiconductor down 2

Acadia stock popped Friday after European regulators unexpectedly said they would recommend approval

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-m

-- European Commission decision expected in the coming months-- If approved, DAYBU® would become the

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Comm

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

ACADIA Pharmaceuticals NASDAQ: ACAD executives used an RBC Capital Markets investor session to outli

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Tra

ACADIA Pharmaceuticals NASDAQ: ACAD executives said the company is focused on expanding its two comm

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nupl

ACADIA Pharmaceuticals (NASDAQ:ACAD) affirms FY2026 sales outlook from $1.220 billion-$1.280 billion

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.02 per share which missed the

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present multiple original dat

-- DAYBUE STIX is a new powder formulation of trofinetide-- Recently published expert consensus reco

Top Wall Street analysts changed outlook on top names. See all rating changes, including upgrades, d

B of A Securities analyst Tazeen Ahmad upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight a

TD Cowen analyst Ritu Baral maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperfo

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Out

Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and lowers

ACADIA Pharmaceuticals (NASDAQ:ACAD) sees FY2026 sales of $1.220 billion-$1.280 billion vs $1.203 bi

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.14 per share which beat the a

Wolfe Research analyst Rudy Li initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a